China National Accord Medicines Corp Ltd

Sinopharm Accord released its 2026 interim report. Total operating revenue was 36.266 billion yuan, down 1.44% year on year, and net profit attributable to the parent company was 606 million yuan, down 8.97% year on year. Net cash flow from operating activities was negative 1.519 billion yuan, a decrease of 1.534 billion yuan compared with the same period last year. The company's asset-liability ratio was 54.55%, gross margin was 10.04%, return on equity was 3.21%, and diluted earnings per share was 0.99 yuan. The number of shareholders was 39,700, and the top ten shareholders held 62.06% of the total share capital.

Sinopharm Group announced that Sinopharm Accord has released its first-half 2026 performance flash report. Net profit attributable to shareholders of the listed company was 606 million yuan, down 8.97% year on year. During the reporting period, Sinopharm Accord achieved total operating revenue of 36.266 billion yuan, down 1.44% year on year. Operating profit was 834 million yuan, down 9.94%. Total profit was 827 million yuan, down 9.88%. Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 599 million yuan, down 6.84%. Basic earnings per share were 0.99 yuan, down 9.17%. The weighted average return on equity was 3.21%, down 0.49 percentage points year on year. At the end of the reporting period, the company's total assets were 48.171 billion yuan, down 1.89% year on year. Equity attributable to shareholders of the listed company was 18.873 billion yuan, up 1.42% year on year. Total share capital was 612 million shares, up 10.00% year on year. Net assets per share attributable to shareholders of the listed company were 30.83 yuan, up 1.41% year on year.